Jan 12 2023 Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors View
Jan 09 2023 Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer View
Dec 07 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder View
Nov 10 2022 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results View
Nov 08 2022 Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 View
Oct 13 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder View
Sep 20 2022 Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder View
Aug 11 2022 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results View
Aug 09 2022 Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder View
Aug 05 2022 Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 View
